Abstract
Meditation practices, known for their stress management and well-being benefits, are being increasingly integrated into wellness regimens and adjunct therapies for chronic conditions. We propose that beneath their non-pharmacological facade, meditation practices might operate via drug target modulation. Here, we leverage the Connectivity Map (CMap) to investigate (a) the overlap between meditation-induced molecular signatures and established drug responses, and (b) the pathways and mechanisms contributing to meditation therapeutic effects. This was studied in a comprehensive temporal RNAseq dataset comprising premeditation, meditation, and follow-up stages from a clinical trial involving 106 participants practising inner engineering meditation. Most striking, we observed intersection of meditation signatures with over 438 drugs, with ≥98% negative and positive connectivity scores and clusters of individuals with differential response. These drugs predominantly target the neuroactive ligand receptor signaling pathway, that are used widely in neuro-psychiatric disorders, hypertension, migraine, pain, insomnia, nicotine addiction, alcoholism, and cancer. This study underscores the need to (a) approach meditation with the same caution as medication, (b) tailor and calibrate meditation practices based on individual health status, disease profile, and concurrent medications, and (c) conduct meditation under expert guidance.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov identifier: NCT04366544.
Funding Statement
The fellowship and infrastructure support for the PI and personnel involved in the study was funded by Ministry of AYUSH. The study per se is meta analysis and did not require any funds. This is acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was carried out on 389 transcriptomes (GSE174083), from 106 individuals of a meditation retreat (ClinicalTrials.gov identifier: NCT04366544.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
MM conceptualised and designed the study, DP, AJ and MM carried out the analysis, AJ and MM wrote the manuscript.
None.
Data Availability
All data produced in the present study are contained on the manuscript.
